Schafer Elizabeth J, Laversanne Mathieu, Sung Hyuna, Soerjomataram Isabelle, Briganti Alberto, Dahut William, Bray Freddie, Jemal Ahmedin
Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Eur Urol. 2025 Mar;87(3):302-313. doi: 10.1016/j.eururo.2024.11.013. Epub 2024 Dec 11.
Our aim was to examine worldwide patterns and trends for prostate cancer (PC) incidence and mortality using high-quality, up-to-date, population-based data.
We analyzed age-standardized PC incidence and mortality rates by country and region from the 2022 GLOBOCAN estimates and temporal trends in incidence (50 countries/territories) and mortality (59 countries/territories) rates using data from the Cancer Incidence in Five Continents series and the World Health Organization mortality database.
Estimated PC rates across regions in 2022 varied 13-fold for incidence and 9.5-fold for mortality. The highest incidence rates were in Australia/New Zealand, North America, Northern Europe, and Latin America/Caribbean. The highest mortality rates were in sub-Saharan Africa and Latin America/Caribbean. During the most recent 5-yr period, incidence rates increased in 11 of the 50 countries included in the study and mortality rates increased in nine of 59 countries, mostly located in Africa, Asia, Latin America/Caribbean, and Central and Eastern Europe. Mortality rates decreased in 38 countries, largely located in Europe, Oceania, and Latin America/Caribbean. Limitations include the lack of data for low- and middle-income countries.
The increase in PC incidence and mortality rates in many countries in Africa, Asia, and Latin America/Caribbean may be because of increases in detection (incidence) and limited access to and availability of treatments (mortality only). The findings reinforce the importance of improving the health care infrastructure in these countries to mitigate the rising burden of PC.
我们的目标是利用高质量、最新的基于人群的数据,研究全球前列腺癌(PC)发病率和死亡率的模式及趋势。
我们根据2022年全球癌症负担(GLOBOCAN)估计数据,分析了按国家和地区划分的年龄标准化PC发病率和死亡率,并利用《五大洲癌症发病率》系列数据和世界卫生组织死亡率数据库,分析了发病率(50个国家/地区)和死亡率(59个国家/地区)的时间趋势。
2022年各地区PC发病率估计值相差13倍,死亡率相差9.5倍。发病率最高的地区是澳大利亚/新西兰、北美、北欧以及拉丁美洲/加勒比地区。死亡率最高的地区是撒哈拉以南非洲和拉丁美洲/加勒比地区。在最近5年期间,研究纳入的50个国家中有11个国家的发病率上升,59个国家中有9个国家的死亡率上升,这些国家大多位于非洲、亚洲、拉丁美洲/加勒比地区以及中东欧。38个国家的死亡率下降,这些国家主要位于欧洲、大洋洲以及拉丁美洲/加勒比地区。局限性包括缺乏低收入和中等收入国家的数据。
非洲、亚洲以及拉丁美洲/加勒比地区许多国家PC发病率和死亡率上升,可能是因为检测率提高(发病率方面)以及治疗可及性和可得性有限(仅死亡率方面)。这些发现强化了改善这些国家卫生保健基础设施以减轻PC负担上升的重要性。